EMT‐ and MET‐related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities

Процессы, связанные с эпителиально-мезенхимным и мезенхимно-эпителиальным переходами, в неэпителиальных опухолях: значение для прогрессирования заболевания, прогноза и терапевтических возможностей
Justin Vareecal Joseph, Ulf D. Kahlert, Frank A.E. Kruyt
2017-05-28

EMT transcription factorsepithelial-to-mesenchymal transitionglioblastomamesenchymal-to-epithelial transitionnonepithelial tumors
The epithelial-to mesenchymal (EMT) process is increasingly recognized for playing a key role in the progression, dissemination, and therapy resistance of epithelial tumors. Accumulating evidence suggests that EMT inducers also lead to a gain in mesenchymal properties and promote malignancy of nonepithelial tumors. In this review, we present and discuss current findings, illustrating the importance of EMT inducers in tumors originating from nonepithelial/mesenchymal tissues, including brain tumors, hematopoietic malignancies, and sarcomas. Among these tumors, the involvement of mesenchymal transition has been most extensively investigated in glioblastoma, providing proof for cell autonomous and microenvironment-derived stimuli that provoke EMT-like processes that regulate stem cell, invasive, and immunogenic properties as well as therapy resistance. The involvement of prominent EMT transcription factor families, such as TWIST, SNAI, and ZEB, in promoting therapy resistance and tumor aggressiveness has also been reported in lymphomas, leukemias, and sarcomas. A reverse process, resembling mesenchymal-to-epithelial transition (MET), seems particularly relevant for sarcomas, where (partial) epithelial differentiation is linked to less aggressive tumors and a better patient prognosis. Overall, a hybrid model in which more stable epithelial and mesenchymal intermediates exist likely extends to the biology of tumors originating from sources other than the epithelium. Deeper investigation and understanding of the EMT/MET machinery in nonepithelial tumors will shed light on the pathogenesis of these tumors, potentially paving the way toward the identification of clinically relevant biomarkers for prognosis and future therapeutic targets.
1
A hybrid model involving stable epithelial, mesenchymal, and intermediate states may apply broadly to nonepithelial tumors and provide clinically relevant biomarkers or therapeutic targets.
2
EMT inducers can confer mesenchymal properties and promote malignancy in tumors originating from nonepithelial or mesenchymal tissues.
3
In glioblastoma, cell-autonomous and microenvironment-derived stimuli trigger EMT-like processes affecting stemness, invasion, immunogenicity, and therapy resistance.
4
MET-like processes are particularly relevant in sarcomas, where partial epithelial differentiation is associated with reduced aggressiveness and better prognosis.
5
TWIST, SNAI, and ZEB transcription factor families contribute to tumor aggressiveness and therapy resistance in lymphomas, leukemias, and sarcomas.

nonepithelial tumors, including glioblastoma, hematopoietic malignancies, and sarcomas

EMT- and MET-related processes and their roles in tumor progression, dissemination, stemness, invasion, immunogenicity, therapy resistance, prognosis, and therapeutic targeting

Publication Details
Publication Date
2017-05-28
Journal
Publisher
ISSN
Cited by
180
Access Type
Author Information
Authors
Justin Vareecal Joseph
Ulf D. Kahlert
Frank A.E. Kruyt
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%